| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Gynecology and Obstetrics (N.C., F.F.), Geriatric Medicine, and Metabolic Diseases (D.M., M.C., G.P.), Second University of Naples, I-80138 Naples, Italy
Address all correspondence and requests for reprints to: Giuseppe Paolisso, M.D., Department of Geriatric Medicine and Metabolic Diseases, IV Internal Medicine, Piazza Miraglia 2, I-80138 Napoli, Italy. E-mail: giuseppe.paolisso{at}unina2.it.
Postmenopausal women have more severe endothelial dysfunction than premenopausal women. In the present study, we evaluated the possible beneficial effect of raloxifene administration, a selective estrogen receptor modulator, on endothelial regulation in postmenopausal women. In a double-blind, randomized vs. placebo trial, 60 healthy postmenopausal women were treated with raloxifene (60 mg/d) or placebo for 4 months to evaluate the effect of raloxifene treatment on endothelial function. Furthermore, in raloxifene-treated subjects (n = 30), the effect of raloxifene was also assessed during the intraarterial infusion of NG-monomethyl-L-arginine (4 µmol/min). Raloxifene administration vs. placebo was associated with a decrease in plasma low-density lipoprotein cholesterol (P < 0.01), triglyceride (P < 0.05), thiobarbituric acid-reactive substance (P < 0.01), vascular cell adhesion molecule-1 (P < 0.05), intercellular adhesion molecule-1 (P < 0.001), and E-selectin (P < 0.001) levels and with an increase in plasma Trolox equivalent antioxidant capacity (P < 0.001) levels. Indeed, raloxifene treatment was also associated with a significant improvement in endothelial-dependent vasodilatation assessed by brachial reactivity technique. Raloxifene administration had no impact on endothelial-independent vasodilatation. Furthermore, intraarterial infusion of NG-monomethyl-L-arginine inhibited the significant effect of raloxifene on endothelium-mediated brachial arterial diameter and flow. In conclusion, our results demonstrate that raloxifene administration is associated with a positive modulation of endothelial-dependent vasodilatation likely due to a reduction of risk factors for endothelial damage.
This work was supported by grants from Second University of Naples.
Abbreviations: BMI, Body mass index; CRP, C-reactive protein; eNOS, endothelial NO synthase; HDL, high-density lipoprotein; ICAM-1, intercellular adhesion molecule-1; LDL, low-density lipoprotein; L-NMMA, NG- monomethyl-L-arginine; NO, nitric oxide; TBARS, thiobarbituric acid-reactive substance; TEAC, Trolox equivalent antioxidant capacity; VCAM-1, vascular cell adhesion molecule-1; WHR, waist to hip ratio.
This article has been cited by other articles:
![]() |
K. Kublickiene, E. Svedas, B.-M. Landgren, M. Crisby, N. Nahar, H. Nisell, and L. Poston Small Artery Endothelial Dysfunction in Postmenopausal Women: In Vitro Function, Morphology, and Modification by Estrogen and Selective Estrogen Receptor Modulators J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6113 - 6122. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. P. Leung, X. Yao, C.-W. Lau, W.-H. Ko, L. Lu, and Y. Huang Raloxifene relaxes rat intrarenal arteries by inhibiting Ca2+ influx Am J Physiol Renal Physiol, July 1, 2005; 289(1): F137 - F144. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Speyer, N. J. Rancilio, S. D. McClintock, J. D. Crawford, H. Gao, J. V. Sarma, and P. A. Ward Regulatory effects of estrogen on acute lung inflammation in mice Am J Physiol Cell Physiol, April 1, 2005; 288(4): C881 - C890. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Jeong, H. Lin, and M. Hu Disposition Mechanisms of Raloxifene in the Human Intestinal Caco-2 Model J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 376 - 385. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |